We plan to use this study as a foundation to design a new class of CtsK inhibitor, which can be further developed into an anti-resorptive therapeutics to curb undesired bone resorption in diseases like osteoporosis, periodontal bone loss, rheumatoid arthritis, Paget’s disease and cancer. The gene discussed is CTSK; the disease is osteoporosis.